Fevertree FY25 EBITDA misses estimates as U.S. profit halves on Molson Coors deal

Fevertree reported adjusted group EBITDA of £42.4m for FY Dec 31, 2025, missing consensus £44.4m (group EBITDA -16% y/y) and diluted EPS fell to 18.62p from 20.85p. U.S. adjusted EBITDA collapsed 56% to £8.2m despite +6% constant-currency U.S. revenue; the margin hit reflected profit-sharing with Molson Coors, transition costs and production reshoring. The company completed a £100m buyback (avg 831p), launched a further £30m programme, raised the full-year dividend 2% to 17.31p, and Jefferies retained a buy with a 1,100p target while trimming 2026 sales to £400m. Fevertree has legally challenged the £2.8m EPR provision (saying a win could add ~5% to 2026 EBIT) and introduced an 'adjusted revenue' reconciliation for U.S. invoicing.

Analysis

The headline margin hit masks a structural transfer of economic value: a partner with scale (distribution/production control) captures downstream unit economics, while the brand-owner retains marketing and pricing optionality. That transfer creates a durable wedge — upside to the scale partner’s gross margins and cash flow, downside to the brand-owner’s EBITDA per unit — and it puts a premium on any countervailing levers (legal relief, buybacks, FX) that restore the brand-owner’s retained margin.

Operationally, bringing production back onshore and the new invoicing conventions introduce timing and working-capital volatility that will amplify quarter-to-quarter reported swings even if underlying demand is steady. This benefits glass/packaging OEMs and UK logistics providers through near-term incremental volumes, but raises the bar on inventory and order-timing forecasting for the brand-owner for the next 6–18 months.

Catalysts to watch with clear time horizons: the regulatory/legal outcome (binary, 6–18 months) that can re-rate margins; FX moves (dollar weakness is an immediate 1–4 quarter headwind to reported top line); and additional buyback capacity or partnership re-pricing (3–12 months) which can truncate downside. The market appears to price a persistent margin impairment; a favorable legal ruling or renegotiation would be a clean, high-leverage rerating event. Conversely, execution slippage in the partnership rollout or worsening on-trade fundamentals would re-open downside over the next year.

Key Decisions for Investors

• Pair trade (6–12 months): Go long Molson Coors (TAP) and short Fevertree (FEVR.L) to capture the margin transfer dynamic — size so the pair is market-neutral by notional. Target asymmetric payoff: +30–50% on TAP leg if distribution captures sustained incremental margin; stop the pair if the spread moves adverse by 15% (covers integration-governance risk).
• Event option (6–18 months): Buy FEVR.L call spread (long-dated, ~12–18 month) sized to risk 1–2% of portfolio to express a favorable legal/regulatory outcome or buyback tailwind. This limits downside to premium while offering 2–5x upside if margins recover or consensus revisions follow a legal win.
• Supply-chain play (12–24 months): Accumulate Ardagh Group (ARD.L) to capture reshoring/extra glass volume and higher-export demand from branded clients shifting production back to the UK/EU. Target +35–45% upside vs downside ~25% if global beverage demand contracts; use 9–12 month trailing stop to lock gains on execution surprises.
• Income-defensive (3–9 months): If shorter-term downside appears (post-earnings volatility), buy FEVR.L and sell 6–9 month covered calls to monetize the buyback-supported floor while retaining upside from a legal win. Size covered-call premium to reduce net cost by mid-single-digit percentage of position value.